Association of creatinine and creatinine clearance on presentation in acute myocardial infarction with subsequent mortality.
暂无分享,去创建一个
E. Antman | R. Giugliano | E. Braunwald | C. Cannon | D. Morrow | S. Murphy | C. Gibson | D. Pinto | S. Wiviott | Duane S Pinto | H. Hobbach | C. Gibson
[1] D. Grobbee,et al. Accelerated decline and prognostic impact of renal function after myocardial infarction and the benefits of ACE inhibition: the CATS randomized trial. , 2003, European heart journal.
[2] R. Sakata,et al. Long-term results of coronary artery bypass grafting in patients with renal insufficiency. , 2003, The Annals of thoracic surgery.
[3] E. Braunwald,et al. Effects of renal insufficiency on early invasive management in patients with acute coronary syndromes (The TACTICS-TIMI 18 Trial). , 2002, The American journal of cardiology.
[4] A. Jaffe,et al. Acute Myocardial Infarction and Renal Dysfunction: A High-Risk Combination , 2002, Annals of Internal Medicine.
[5] M. Mcclellan,et al. Association of Renal Insufficiency with Treatment and Outcomes after Myocardial Infarction in Elderly Patients , 2002, Annals of Internal Medicine.
[6] R. Califf,et al. Prognostic Implications of Abnormalities in Renal Function in Patients With Acute Coronary Syndromes , 2002, Circulation.
[7] M. Bell,et al. The impact of renal insufficiency on clinical outcomes in patients undergoing percutaneous coronary interventions. , 2002, Journal of the American College of Cardiology.
[8] H. Hirose,et al. Coronary artery bypass grafting for patients with non-dialysis-dependent renal dysfunction (serum creatinine > or =2.0 mg/dl). , 2001, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.
[9] G. O'connor,et al. Risks of Morbidity and Mortality in Dialysis Patients Undergoing Coronary Artery Bypass Surgery , 2000, Circulation.
[10] InTIME-II Investigators,et al. Intravenous NPA for the treatment of infarcting myocardium early; InTIME-II, a double-blind comparison of single-bolus lanoteplase vs accelerated alteplase for the treatment of patients with acute myocardial infarction. , 2000, European heart journal.
[11] E. Antman,et al. Combination reperfusion therapy with abciximab and reduced dose reteplase: results from TIMI 14. The Thrombolysis in Myocardial Infarction (TIMI) 14 Investigators. , 2000, European heart journal.
[12] E. Antman,et al. TIMI Risk Score for ST-Elevation Myocardial Infarction: A Convenient, Bedside, Clinical Score for Risk Assessment at Presentation: An Intravenous nPA for Treatment of Infarcting Myocardium Early II Trial Substudy , 2000, Circulation.
[13] C M Gibson,et al. Relationship of TIMI myocardial perfusion grade to mortality after administration of thrombolytic drugs. , 2000, Circulation.
[14] E. Antman,et al. Abciximab facilitates the rate and extent of thrombolysis: results of the thrombolysis in myocardial infarction (TIMI) 14 trial. The TIMI 14 Investigators. , 1999, Circulation.
[15] E. Braunwald,et al. Relationship between TIMI frame count and clinical outcomes after thrombolytic administration. Thrombolysis In Myocardial Infarction (TIMI) Study Group. , 1999, Circulation.
[16] Robert J. Anderson,et al. Clinical Nephrology – Epidemiology – Clinical TrialsRenal failure predisposes patients to adverse outcome after coronary artery bypass surgery , 1999 .
[17] Thomas E. Moritz,et al. Renal failure predisposes patients to adverse outcome after coronary artery bypass surgery , 1999 .
[18] R. Giugliano,et al. TNK-tissue plasminogen activator compared with front-loaded alteplase in acute myocardial infarction: results of the TIMI 10B trial. Thrombolysis in Myocardial Infarction (TIMI) 10B Investigators. , 1998, Circulation.
[19] H. White,et al. Abnormal coronary flow in infarct arteries 1 year after myocardial infarction is predicted at 4 weeks by corrected Thrombolysis in Myocardial Infarction (TIMI) frame count and stenosis severity. , 1998, The American journal of cardiology.
[20] J. Dodge,et al. Thrombolysis in Myocardial Infarction frame count in saphenous vein grafts. , 1998, American heart journal.
[21] M. Borger,et al. Coronary artery bypass grafting in patients with non-dialysis-dependent renal insufficiency. , 1997, Circulation.
[22] E. Braunwald,et al. TNK-tissue plasminogen activator in acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI) 10A dose-ranging trial. , 1997, Circulation.
[23] E. Braunwald,et al. TIMI frame count: a quantitative method of assessing coronary artery flow. , 1996, Circulation.
[24] T Sandor,et al. Quantitative angiographic and statistical methods to assess serial changes in coronary luminal diameter and implications for atherosclerosis regression trials. , 1992, The American journal of cardiology.
[25] W. Ganz,et al. The thrombolysis in myocardial infarction (TIMI) trial. , 1985, The New England journal of medicine.
[26] H. S. Mueller,et al. The Thrombolysis in Myocardial Infarction (TIMI) trial. Phase I findings. , 1985, The New England journal of medicine.
[27] E. Rubinstein,et al. Prediction of creatinine clearance from serum creatinine concentration based on lean body mass , 1981, Clinical pharmacology and therapeutics.